1. Home
  2. ONC vs FMX Comparison

ONC vs FMX Comparison

Compare ONC & FMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BeiGene Ltd. American Depositary Shares

ONC

BeiGene Ltd. American Depositary Shares

N/A

Current Price

$416.47

Market Cap

40.6B

Sector

Health Care

ML Signal

N/A

Logo Fomento Economico Mexicano S.A.B. de C.V.

FMX

Fomento Economico Mexicano S.A.B. de C.V.

N/A

Current Price

$131.74

Market Cap

41.4B

ML Signal

N/A

Company Overview

Basic Information
Metric
ONC
FMX
Founded
2010
1890
Country
Switzerland
Mexico
Employees
12000
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Beverages (Production/Distribution)
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
40.6B
41.4B
IPO Year
2015
1998

Fundamental Metrics

Financial Performance
Metric
ONC
FMX
Price
$416.47
$131.74
Analyst Decision
Strong Buy
Buy
Analyst Count
27
15
Target Price
★ $465.00
$135.93
AVG Volume (30 Days)
442.0K
★ 793.7K
Earning Date
11-05-2026
10-28-2026
Dividend Yield
N/A
★ 5.12%
EPS Growth
★ 140.43
N/A
EPS
★ 0.56
N/A
Revenue
★ $238,387,000.00
N/A
Revenue This Year
$29.05
$7.78
Revenue Next Year
$15.06
$7.89
P/E Ratio
$743.85
★ $40.94
Revenue Growth
★ 22179.16
N/A
52 Week Low
$253.95
$92.55
52 Week High
$424.73
$141.47

Technical Indicators

Market Signals
Indicator
ONC
FMX
Relative Strength Index (RSI) 67.27 64.47
Support Level $341.67 $121.26
Resistance Level N/A $134.52
Average True Range (ATR) 10.70 2.95
MACD 4.37 0.31
Stochastic Oscillator 88.77 82.87

Price Performance

Historical Comparison
ONC
FMX

About ONC BeiGene Ltd. American Depositary Shares

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

About FMX Fomento Economico Mexicano S.A.B. de C.V.

Mexico-based Femsa is a beverage and retail conglomerate in Central and South America. The holding company owns controlling stakes in bottler Coca-Cola Femsa (47% economic stake, 56% voting rights), in addition to operating 100%-owned retail assets, including convenience stores under the Oxxo banner, drugstores, and gas stations. The firm divested its 15% stake in Heineken and its distribution business in 2023. Coca-Cola Femsa and the Oxxo chain made up over 70% of total company revenue and over 90% of profits in 2025.

Share on Social Networks: